What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued ...

June 26 (Reuters) - Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it ...

Biogen is running a campaign aimed at spreading awareness of the next-gen version of its spinal muscular atrophy therapy Spinraza.  | Biogen is running a campaign aimed at spreading awareness of the ...

Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may ...

The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics ...

Biogen has dipped its toe into the M&A waters once again, agreeing to buy San Diego-based RayThera for up to $1 billion in ...

Biogen will acquire San Diego's RayThera for up to $1B, expanding its immunology pipeline with early-stage anti-inflammatory ...

Biogen has struck a backloaded, $1 billion deal to buy RayThera, snagging a pipeline of anti-inflammatory drug candidates led by a prospect on the cusp of clinical development.

View Biogen Inc. BIIB stock quote prices, financial information, real-time forecasts, and company news from CNN.

Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, today announced the companies have entered ...